Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Receives $48.00 Average Price Target from Analysts

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) have been assigned an average rating of “Buy” from the eight ratings firms that are presently covering the company, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $46.6667.

A number of analysts have issued reports on the company. BTIG Research reaffirmed a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a research note on Monday, April 13th. Rodman & Renshaw assumed coverage on shares of Ascentage Pharma Group International in a report on Tuesday, January 13th. They issued a “buy” rating and a $48.00 price objective for the company. Deutsche Bank Aktiengesellschaft began coverage on shares of Ascentage Pharma Group International in a research report on Friday, April 24th. They set a “buy” rating and a $40.00 price target on the stock. Finally, China Intl Cap upgraded Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th.

Ascentage Pharma Group International Stock Up 2.1%

Shares of Ascentage Pharma Group International stock opened at $22.95 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79. The stock’s 50 day simple moving average is $24.32 and its 200-day simple moving average is $27.63. Ascentage Pharma Group International has a 1-year low of $19.11 and a 1-year high of $48.45.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The company had revenue of $24.72 million during the quarter. On average, equities analysts anticipate that Ascentage Pharma Group International will post -1.09 earnings per share for the current year.

Institutional Trading of Ascentage Pharma Group International

A number of hedge funds and other institutional investors have recently modified their holdings of AAPG. XY Capital Ltd lifted its position in Ascentage Pharma Group International by 224.2% in the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after buying an additional 12,530 shares during the last quarter. UBS Group AG increased its position in shares of Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares during the last quarter. Hsbc Holdings PLC acquired a new stake in shares of Ascentage Pharma Group International during the second quarter valued at about $391,000. Citadel Advisors LLC purchased a new stake in shares of Ascentage Pharma Group International in the 3rd quarter valued at approximately $383,000. Finally, ABC Arbitrage SA acquired a new position in shares of Ascentage Pharma Group International in the 3rd quarter worth approximately $204,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical?stage biopharmaceutical company focused on developing small?molecule therapeutics that modulate programmed cell death pathways, including the Bcl?2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.